The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in melanoma:
PROTOCOL: CA209-76K (PI: DR VICTORIA ATKINSON)
Short Title: CheckMate 76K
Protocol Title: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma
Lay Title: Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Click here for more information
PROTOCOL: CA209-7CK (PI: DR VICTORIA ATKINSON)
Protocol Title: A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia
Lay Title: An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Click here for more information
PROTOCOL: CA045-022(PI: DR VICTORIA ATKINSON)
Short Title: PIVOT-12
Protocol Title: A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Lay Title: Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Click here for more information